Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $83.4MThe company’s own SEC segment disclosure.
- Hand Pieces And Other Consumables$48.4M58%
- System Sales And Leases$29.1M35%
- Service$6.0M7%
PROCEPT BioRobotics Corporation (PRCT) reported revenue of $83M in Q1 2026 (quarter ended March 31, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 65% and net loss of $32M. For the full year FY2025, revenue was $308M (+37% year on year) and net income −$96M. Its largest product in 2026-Q2 was Hand Pieces And Other Consumables at $48M, 58% of the disclosed total, just ahead of System Sales And Leases at 35%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.